DK2833884T3 - Anvendelse af ccr3-inhibitorer - Google Patents

Anvendelse af ccr3-inhibitorer Download PDF

Info

Publication number
DK2833884T3
DK2833884T3 DK13713199.1T DK13713199T DK2833884T3 DK 2833884 T3 DK2833884 T3 DK 2833884T3 DK 13713199 T DK13713199 T DK 13713199T DK 2833884 T3 DK2833884 T3 DK 2833884T3
Authority
DK
Denmark
Prior art keywords
ccr3 inhibitors
ccr3
inhibitors
Prior art date
Application number
DK13713199.1T
Other languages
Danish (da)
English (en)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2833884(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkahest Inc filed Critical Alkahest Inc
Application granted granted Critical
Publication of DK2833884T3 publication Critical patent/DK2833884T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Structure Of Transmissions (AREA)
DK13713199.1T 2012-04-03 2013-04-02 Anvendelse af ccr3-inhibitorer DK2833884T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03
PCT/EP2013/056864 WO2013149986A1 (en) 2012-04-03 2013-04-02 Use of ccr3-inhibitors

Publications (1)

Publication Number Publication Date
DK2833884T3 true DK2833884T3 (da) 2020-08-10

Family

ID=48040249

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13713199.1T DK2833884T3 (da) 2012-04-03 2013-04-02 Anvendelse af ccr3-inhibitorer

Country Status (28)

Country Link
US (5) US20130261153A1 (enExample)
EP (3) EP3763369B1 (enExample)
JP (2) JP2015512432A (enExample)
KR (5) KR20140144200A (enExample)
CN (2) CN104220073A (enExample)
AU (1) AU2013245027B2 (enExample)
BR (1) BR112014023795B1 (enExample)
CA (1) CA2869269C (enExample)
CL (1) CL2014002523A1 (enExample)
CY (1) CY1123222T1 (enExample)
DK (1) DK2833884T3 (enExample)
EA (1) EA032263B1 (enExample)
ES (2) ES2987267T3 (enExample)
HR (1) HRP20201165T1 (enExample)
HU (1) HUE051648T2 (enExample)
IL (1) IL234262A (enExample)
IN (1) IN2014DN06989A (enExample)
LT (1) LT2833884T (enExample)
MX (1) MX2014011786A (enExample)
NZ (1) NZ628882A (enExample)
PH (1) PH12014502239A1 (enExample)
PL (1) PL2833884T3 (enExample)
PT (1) PT2833884T (enExample)
RS (1) RS60665B1 (enExample)
SI (1) SI2833884T1 (enExample)
SM (1) SMT202000499T1 (enExample)
WO (1) WO2013149986A1 (enExample)
ZA (1) ZA201406082B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
US11045284B2 (en) 2016-11-24 2021-06-29 Kirishima Seiko Co., Ltd. Dental brace and method for attaching dental brace
BR112019020798A2 (pt) * 2017-04-05 2020-04-28 Alkahest Inc métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3
ES3046717T3 (en) * 2017-04-05 2025-12-02 Alkahest Inc Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
US20190111042A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors
US11426399B2 (en) 2018-05-15 2022-08-30 Alkahest, Inc. Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase
EP3856195A4 (en) * 2018-09-26 2022-06-22 Alkahest, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF AGING-RELATED DISORDERS USING CCR3 INHIBITORS
US20230312697A1 (en) 2020-06-11 2023-10-05 Alkahest Inc. Methods of improving retina-associated disease outcome using ccr3-inhibitors
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
BRPI0108923B8 (pt) * 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
PT2833884T (pt) 2020-08-26
EP4389217A2 (en) 2024-06-26
US20200375971A1 (en) 2020-12-03
ES2811554T3 (es) 2021-03-12
HUE051648T2 (hu) 2021-03-29
HRP20201165T1 (hr) 2020-12-11
SMT202000499T1 (it) 2020-11-10
IL234262A (en) 2017-10-31
US20160081998A1 (en) 2016-03-24
RS60665B1 (sr) 2020-09-30
EP2833884B1 (en) 2020-05-20
AU2013245027B2 (en) 2017-10-12
EP3763369B1 (en) 2024-02-28
KR20200044988A (ko) 2020-04-29
NZ628882A (en) 2016-05-27
US20130261153A1 (en) 2013-10-03
CA2869269C (en) 2020-06-30
EP2833884A1 (en) 2015-02-11
PH12014502239A1 (en) 2014-12-15
ES2987267T3 (es) 2024-11-14
EP3763369A1 (en) 2021-01-13
CN104220073A (zh) 2014-12-17
IN2014DN06989A (enExample) 2015-04-10
KR20220132012A (ko) 2022-09-29
EA201401083A1 (ru) 2015-03-31
CY1123222T1 (el) 2021-10-29
AU2013245027A1 (en) 2014-09-11
BR112014023795A8 (pt) 2017-10-10
LT2833884T (lt) 2020-09-10
ZA201406082B (en) 2019-01-30
US20170319567A1 (en) 2017-11-09
CL2014002523A1 (es) 2015-01-23
EA032263B1 (ru) 2019-05-31
EP4389217A3 (en) 2024-08-28
US20150099783A1 (en) 2015-04-09
CN110384699A (zh) 2019-10-29
PL2833884T3 (pl) 2020-11-02
KR20250133980A (ko) 2025-09-09
BR112014023795A2 (enExample) 2017-06-20
WO2013149986A1 (en) 2013-10-10
CA2869269A1 (en) 2013-10-10
KR20140144200A (ko) 2014-12-18
BR112014023795B1 (pt) 2021-09-08
JP2015512432A (ja) 2015-04-27
MX2014011786A (es) 2014-12-05
KR20210063481A (ko) 2021-06-01
SI2833884T1 (sl) 2020-10-30
JP2018080183A (ja) 2018-05-24

Similar Documents

Publication Publication Date Title
SMT201700109B (it) Inibitori di istone demetilasi
DK3357511T3 (da) Inhibitorer af t-celleaktivering
DK3080100T3 (da) Hæmmere af lysinspecifik demethylase-1
DK2833884T3 (da) Anvendelse af ccr3-inhibitorer
DK2912019T3 (da) Heteroarylhæmmere af pde4
LT2841428T (lt) Dnr-pk inhibitoriai
SMT201700094B (it) Composto di pirazina carbossammide
DK3725778T4 (da) Formuleringer af enzalutamid
DK3027618T3 (da) Polymorf af syk-hæmmere
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
SMT201600114B (it) Inibitori di beta-secretasi
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
HUE036259T2 (hu) Inhibitor vegyületek
CO7010824A2 (es) Inhibidores de aplicación viral
DK2866825T3 (da) Anvendelse af langstidsvirkende glp-1-peptider
DK3235812T3 (da) Deutererede derivater af ivacaftor
DK2981255T3 (da) Terapeutiske anvendelser af empagliflozin
DK3461895T3 (da) Modulation af ube3a-ats-ekspression
EP2877458A4 (en) CYSTATHIONINE-Y-GAMMA-LYASE (CSE) -HEMMER
DK3068776T3 (da) Inhibitorer af replikation af influenzavira
DK2928477T3 (da) Anvendelse af telomeraseinhibitor imetelstat til behandling af myelofibrosis
DK2822568T3 (da) Anvendelser af caseinsammensætninger
EP2753176A4 (en) HIV INHIBITORS
DK2834229T3 (da) Fremgangsmåde til fremstilling af ccr3-inhibitorer
EP2858975A4 (en) FBXO3 INHIBITORS